


Corporate Overview

WEX Pharmaceuticals Inc. (WEX) is a late stage biopharmaceutical company focused on developing Halneuron®, for the treatment of neuropathic and nociceptive pain. Halneuron is approved by the US Food Drug Administration and Health Canada to commence pivotal Phase 3 trials for Chemotherapy Induced Neuropathic Pain (CINP). Halneuron has also demonstrated clinically meaningful effects on moderate to severe Cancer Related Pain (CRP) in previous trials.

Halneuron®


- ▶ Active ingredient, tetrodotoxin (TTX), is a potent small molecule concentrated in creatures such as puffer fish (Not a peptide or protein)
- ▶ A sodium (Na⁺) channel blocker agent
- ▶ Binds to voltage-gated sodium channels on the surface of nerve cell membranes
- ▶ Acts on peripheral voltage-gated sodium channels
- ▶ Does not cross the blood-brain barrier (No effect on the central nervous system)
- ▶ Prevents and relieves pain by interrupting nerve conduction



Lead Asset	Blocks Nav 1.7	Efficacious	Safe	Market Potential
<ul style="list-style-type: none"> ▶ Halneuron a Phase 3 proprietary non-opioid pain therapeutic ▶ Superior safety to opioids ▶ No addiction, withdrawal symptoms or tolerance ▶ Long duration of pain relief 	<ul style="list-style-type: none"> ▶ Proven blocker of voltage gated sodium channels ▶ Specifically blocks the peripheral Nav 1.7 channel and does not affect other Nav Channels ▶ Suppresses peripheral pain signals 	<ul style="list-style-type: none"> ▶ Successfully tested on over 700 patients in over 15 clinical trials ▶ Converging clinical efficacy data ▶ High probability of success in CINP and Cancer Related Pain indications 	<ul style="list-style-type: none"> ▶ Safe and well tolerated ▶ Side effects are mild to moderate, short in duration and not requiring medical attention ▶ No tolerance, euphoria, sedation or addiction. 	<ul style="list-style-type: none"> ▶ Enormous market opportunity ▶ No drugs are currently approved for CINP (~\$1.25bn) ▶ Opioids are not recommended for CINP ▶ Non-opioid co-analgesic for Cancer Related Pain (~\$6bn)

Market Opportunity

► Existing CINP treatments use anti-epileptic, anti-depressant and opioids which have shown to be inadequate. Halneuron will be the first analgesic approved for CINP which has a market potential of over ~\$1.25bn. Following CINP, Halneuron will be used for moderate to severe Cancer Related Pain which has a market potential of over ~\$6.0bn.



Halneuron provides a pipeline of numerous indications to treat

INDICATION	DEVELOPMENT	PRE-CLINICAL	PHASE I	PHASE II	PHASE III
Chemotherapy Induced Neuropathic Pain	[Progress bar]				
Cancer Related Pain	[Progress bar]				
Burn Pain	[Progress bar]				
General Chronic Pain	[Progress bar]				
Osteoarthritis	[Progress bar]				
Lower Back Pain	[Progress bar]				
Painful Diabetic Neuropathy	[Progress bar]				

- CINP trials currently being planned for North America, Asia and Europe
- Cancer Related Pain will be WEX's second indication to address
- Future indications include burn pain, osteoarthritis, back pain, post surgical pain and diabetic neuropathy

Patents & Trademarks

► WEX protects the exclusivity of Halneuron by maintaining a family of patents related to dosage characteristics, derivatives, uses, manufacturing processes, sourcing as well as a trade secrets related to extraction, storage, and handling in active pharmaceutical markets and countries across the globe



HALNEURON®

An attractive opportunity with enormous commercial potential

- ✓ Addresses a large unmet need in pain management
- ✓ A real response to the opioid crisis
- ✓ First CINP drug to market
- ✓ Huge pipeline for other pain indications
- ✓ Nav 1.7 is a well-validated target
- ✓ Low-risk and safe with preliminary evidence of efficacy
- ✓ Manufacturable at scale
- ✓ Strong intellectual property and trade secrets
- ✓ Experienced leadership and team

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a public company listed on the Hong Kong Stock Exchange (0775.HK). WEX is based in Vancouver, B.C. Canada and has operations in Canada and Hong Kong.

www.wexpharma.com for further information about the company and products.

www.ck-lifesciences.com for further information about WEX's parent company.

Forward Looking Statements

Certain of the statements contained in this material are forward looking statements which involve known and unknown risks, uncertainties and factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, or achievements expressed or implied.

Leadership

Walter Korz
Chief Operating Officer
+1 604 683 8868
walterk@wexpharma.com

Andrew Buckland
Chief Financial Officer
+1 858 204 3335
andrewb@wexpharma.com

Dr. Meng Zhou
Vice President, Manufacturing
+1 604 676 7917
mengz@wexpharma.com

Abner Yong
Vice President, Finance
+1 604 676 7913
abnery@wexpharma.com